METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo targets tough prostate cancer in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called KTX2001, alone or with another drug (darolutamide), in men with advanced prostate cancer that no longer responds to standard hormone therapy. The main goals are to check safety, find the best dose, and see if it helps control the can…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Phase: PHASE1 • Sponsor: K36 Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 01:27 UTC
-
New pill shows promise against resistant cancers in early trial
Disease control Recruiting nowThis early-phase trial tests a new oral drug, TSL2109, in people with advanced solid tumors, especially metastatic castration-resistant prostate cancer and HR+/HER2- breast cancer. The study aims to find the safest dose and check for early signs of tumor shrinkage. Participants t…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS
Phase: PHASE1 • Sponsor: Tasly Pharmaceutical Group Co., Ltd • Aim: Disease control
Last updated May 20, 2026 11:57 UTC